Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-102 for the Treatment of Rett Syndrome
September 08 2021 - 4:00PM
Business Wire
Virtual event on Wednesday, September 22, 2021,
at 10:00 a.m. ET will provide an overview of Rett syndrome, discuss
natural history, and the TSHA-102 program and clinical development
strategy
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
pivotal-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced it will host a
virtual key opinion leader (KOL) webinar on TSHA-102 for the
treatment of Rett syndrome on Wednesday, September 22, 2021, from
10:00 a.m. to 12:30 p.m. ET.
The event will feature a presentation from key opinion leader
Jeffrey Neul, M.D., Ph.D., Director, Vanderbilt Kennedy Center,
Annette Schaffer Eskind Chair, Professor of Pediatrics,
Pharmacology, and Special Education, Pediatric Neurology at the
Vanderbilt University Medical Center, who will provide an overview
of Rett syndrome and the underlying pathology of this genetic
neurodevelopmental disorder, as well as discuss the natural history
of the disease.
The event will also feature presentations from:
- Monica Coenraads, Chief Executive Officer of Rett Syndrome
Research Trust (RSRT), who will discuss the burden of disease and
provide a patient and caregiver perspective
- Steven Gray, Ph.D., Associate Professor in the Department of
Pediatrics at UT Southwestern and Chief Scientific Advisor at
Taysha, who will review the miRARE platform and preclinical data
generated to date for TSHA-102 in Rett syndrome
- Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical
Officer and Head of R&D of Taysha, who will discuss the
clinical development strategy for TSHA-102 in Rett syndrome and
provide a regulatory update
To register for the investor day, please click here. A live
video webcast will be available in the “Events & Media” section
of the Taysha corporate website. An archived version of the event
will be available on the website for 60 days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210908006055/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com
Media Contact: Carolyn Hawley Canale Communications
carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Sep 2023 to Sep 2024